期刊
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
卷 27, 期 3, 页码 693-701出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1078155220979048
关键词
Pharmacokinetics; therapeutic drug monitoring; anti-cancer agents
Most anticancer agents exhibit wide variability in pharmacokinetics and have a narrow therapeutic index, making fixed dosing suboptimal. While using pharmacokinetic or therapeutic drug monitoring-guided dosing may achieve best therapeutic outcomes, challenges arise from multiple factors contributing to pharmacokinetic variability. Standard guidelines for pharmacokinetic-guided dosing are lacking for most agents, emphasizing the importance of understanding factors contributing to pharmacokinetic variability for dose individualization.
Most anticancer agents show wide variability in pharmacokinetics (PK) and have a narrow therapeutic index which makes fixed dosing suboptimal. To achieve the best therapeutic outcomes with these agents, many studies have postulated using PK or therapeutic drug monitoring (TDM)-guided dosing. However, multiple factors contribute to the variability in PKs making the application of TDM in practice challenging. Also, despite the known association with clinical outcomes, standard guidelines on PK-guided dosing are lacking for most agents. Understanding the factors that contribute to PK variability and their impact is essential for dose individualization. The purpose of this review is to discuss the factors that contribute to the PK variability of anticancer agents and the challenges faced in practice when individualizing doses for certain widely used agents. Searching the literature has identified several gaps and efforts are needed to ensure better targeting of cancer therapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据